Junchan Yune, MD
Urogynecology and Reconstructive Pelvic Surgery · Loma Linda, CANPI 1831398700
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (36.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Medtronic at 56.6% of the total. Reporting peaked in 2019 at $4,193 and has fallen 98.6% since, to $58 in 2025.
Across 60 payments — averaging $82.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$1K
- Coloplast$452
- AbbVie$242
- Ferring Pharmaceuticals Inc.$182
- Axonics, Inc.$35
What the payments were for
- Speaking & faculty fees$1,20024%
- Grants$120%
- Travel & lodging$1,78836%
- Food & beverage$1,71335%
- Education$2385%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 37 | $2,801 |
| Boston Scientific | 3 | $1,240 |
| Coloplast | 7 | $452 |
| AbbVie(2 entities) | 11 | $242 |
| Ferring Pharmaceuticals Inc. | 1 | $182 |
| Axonics, Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,952 in reported general payments places this provider in the 55th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 634 | $339,854 |
| Methenamine Hippurate | 412 | $26,281 |
| Trospium Chloride ErTrospium Chloride | 116 | $15,234 |
| Trospium Chloride | 178 | $10,321 |
| GemtesaVibegron | 12 | $8,782 |
| PremarinEstrogens, Conjugated | 15 | $6,438 |
| Estradiol | 98 | $5,962 |
| Darifenacin ErDarifenacin Hydrobromide | 13 | $4,426 |
| Oxybutynin Chloride ErOxybutynin Chloride | 217 | $2,916 |
| Solifenacin Succinate | 82 | $2,014 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 130 | $1,521 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $1,138 |
| Ibuprofen | 104 | $451 |
| Tramadol Hcl | 46 | $142 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $142 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Loma Linda
- Kaythi KhinLoma Linda$5K
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.